Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients

Management of PD-1 blockade resistance in metastatic melanoma (MM) remains challenging. Immunotherapy or chemotherapy alone provides limited benefit in this setting. Chemo-immunotherapy (CIT) has demonstrated favorable efficacy and safety profiles in lung cancer. Our pre-clinical study showed that i...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Melanoma Res
Autori principali: Vera Aguilera, Jesus, Paludo, Jonas, McWilliams, Robert R., Zhang, Henan, Li, Ying, Kumar, Anagha B., Failing, Jarrett, Kottschade, Lisa A., Block, Matthew S., Markovic, Svetomir N., Dong, Haidong, Dronca, Roxana S., Yan, Yiyi
Natura: Artigo
Lingua:Inglês
Pubblicazione: Lippincott Williams & Wilkins 2020
Soggetti:
Original Articles: Clinical research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7331824/
https://ncbi.nlm.nih.gov/pubmed/32404734
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CMR.0000000000000669
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi